Key facts
- This page summarizes Karen L. Smith's Form 4 filing for Quince Therapeutics, Inc. (QNCX).
- 1 reported transaction and 1 derivative row are listed below.
- Accepted by SEC: 02 Feb 2023, 17:35.
Karen L. Smith - 01 Feb 2023 Form 4 Insider Report for Quince Therapeutics, Inc. (QNCX)
- Reporting relationship
- Chief Medical Officer
- Issuer ticker
- QNCX
- Reported as of
- 01 Feb 2023
- Net transaction value
- $0
- SEC form
- 4
- Accepted by SEC
- 02 Feb 2023, 17:35:56 UTC
- Prior SEC filing
- 13 Jun 2022
- Next SEC filing
- 05 Jun 2023
- Source filing
- View source filing
- Reporting owner signature
- /s/ Ted Monohon, Attorney-in-Fact for Karen L. Smith
Source evidence
Original filing metadata and source links for verification.
5 source fields
Reporting owner
1 detail
Key filing fact
Karen L. Smith filed Form 4 for Quince Therapeutics, Inc. (QNCX) on 02 Feb 2023.
Change
- Previous filing in this sequence was filed on 13 Jun 2022.
- Current net transaction value: $0.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reported derivative securities
Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.
QNCX
transaction
Derivative
Employee Stock Option (right to buy)
Award
- Transaction value
- $0
- Shares
- +225,000
- Change %
- Price
- $0.000000
- Shares after
- 225,000
- Date
- 01 Feb 2023
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 225,000
- Exercise price
- $0.9400
- Footnotes
- F1
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 1 footnote
Footnote F1
The shares subject to this option shall vest in equal monthly installments, at a rate of 1/48th of the total number of shares on each monthly anniversary of the vesting commencement date of January 1, 2023, such that the total number of shares shall be fully vested on the four-year anniversary of the vesting commencement date.